| Name |
Visilizumab (USAN/INN);Nuvion (TN) |
| Efficacy |
Immunosuppressant, Anti-CD3 antibody |
| Type |
Monoclonal antibody |
| Comment |
Treatment of organ transplantation rejection and other T lymphocyte-mediated diseases and disorders, including autoimmune diseases |
| Target |
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452] |
| Pathway |
hsa04660 T cell receptor signaling pathway |
| Brite |
Target-based classification of drugs [BR:br08310] Cell surface molecules and ligands Other cell surface molecules CD molecules CD3 D06314 Visilizumab (USAN/INN) |
| Other DBs |
CAS: 219716-33-3PubChem: 47207971 |
| LinkDB |
|